Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15927847 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL15927846 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL12030067 | 0.90 | ALDH1A1 (0.39) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL17172717 | 0.85 | LMNA (0.38) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL4291628 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL1964295 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL28017152 | 0.83 | ALOX15 (0.35) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL27282843 | 0.82 | CYP1A2 (0.44) | SMN1; SMN2LMNAKDM4EMAPTPOLB | |
| SCHEMBL32676486 | 0.81 | SMN1; SMN2 (0.34) | SMN1; SMN2GAALMNAKDM4EMEN1 | |
| SCHEMBL8050020 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2GAALMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2139854-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | CTRL, PREP, CES1 | SMN1; SMN2 3374/4885GAA 151/4885LMNA 2992/4885 |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | SMN1; SMN2 3434/4885GAA 1444/4885LMNA 3587/4885 |
| US-20160046641-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | SMN1; SMN2 3249/4885GAA 1587/4885LMNA 3326/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | SMN1; SMN2 3538/4885GAA 1810/4885LMNA 3062/4885 |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, SAV1 | SMN1; SMN2 3477/4885GAA 2174/4885LMNA 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.